A Study of Chidamide With AZA in MRD Positive AML After Transplant

Summary

acute myeloid leukemia (AML) is a malignant tumor of the hematopoietic system with high heterogeneity in cytogenetics and molecular biology.Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is still the primary treatment option for patients with AML and the most effective method for radical treatment of AML.Despite considerable progress in allo-HSCT over the past decade, 30%-40% of patients still relapse, and post-transplant relapse remains the leading cause of death in patients with AML.

Timeline

Start

2023-10-26

Primary completion

2026-12

Completion

2026-12

Publications

• Ling W, Wu P, Wu S, Luo C, Huang L, Chen X, Liang X, Li Z, Xu R, Tan J, Wang J, Lai P, Du X, Weng J. MRD-driven HDACi-based therapy post-transplant: a real-world study in high-risk acute myeloid leukemia. Ann Hematol. 2026 Jul 13. doi: 10.1007/s00277-026-07117-7. Online ahead of print.

Drugs

Indications